abstract |
The present invention provides a genetically engineered non-natural bacterium comprising inactivating mutations in one or more genes selected from pltA , pltB , cdtB and tts A , wherein the bacterium is derived from Salmonella spp, i n particular Salmonella enterica, such as S. enterica Typ hi, S. enterica Paratyphi A, S. enterica Paratyphi B or S. enterica Paratyphi C. The one or more inactivating mutations may comprise the partial or complete deletion of the one or more genes selected from pltA , pltB , cdtB and ttsA . The non-natural bacterium of the invention is provided for use in the treatment or prevention of a disease, such as an infectious disease or cancer. For example the bacterium may be for use in vaccination against a disease, such as typhoid or paratyphoid enteric fever. The bacterium may also be used as an anti-cancer therapy comprising suitable heterologous proteins. |